{"groups":[{"description":"Recurrent or progressive DIPG patients received panobinostat orally every other day, 3 times per week at 10 mg/m\\^2/day for three weeks on, one week off (1 course = 28 days) for up to 26 courses in the absence of disease progression or unacceptable toxicity.","id":"FG000","title":"Stratum 1, Dose Level 1 (10 mg/m^2)"},{"description":"Recurrent or progressive DIPG patients received panobinostat orally every other day, 3 times per week at 16 mg/m\\^2/day for three weeks on, one week off (1 course = 28 days) for up to 26 courses in the absence of disease progression or unacceptable toxicity.","id":"FG001","title":"Stratum 1, Dose Level 2 (16 mg/m^2)"},{"description":"Non-progressed DIPG or H3K27M+ thalamic DMG patients received panobinostat orally every other day, 3 times per week at 16 mg/m\\^2/day for every other week (1 course = 28 days) for up to 26 courses in the absence of disease progression or unacceptable toxicity.","id":"FG002","title":"Stratum 2, Dose Level 1 (16 mg/m^2)"},{"description":"Non-progressed DIPG or H3K27M+ thalamic DMG patients received panobinostat orally every other day, 3 times per week at 22 mg/m\\^2/day for every other week (1 course = 28 days) for up to 26 courses in the absence of disease progression or unacceptable toxicity.","id":"FG003","title":"Stratum 2, Dose Level 2 (22 mg/m^2)"},{"description":"Non-progressed DIPG or H3K27M+ thalamic DMG patients received panobinostat orally every other day, 3 times per week at 28 mg/m\\^2/day for every other week (1course = 28 days) for up to 26 courses in the absence of disease progression or unacceptable toxicity.","id":"FG004","title":"Stratum 2, Dose Level 3 (28 mg/m^2)"},{"description":"Non-progressed DIPG or H3K27M+ thalamic DMG patients received panobinostat orally every other day, 3 times per week at 36 mg/m\\^2/day for every other week (1course = 28 days) for up to 26 courses in the absence of disease progression or unacceptable toxicity.","id":"FG005","title":"Stratum 2, Dose Level 4 (36 mg/m^2)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"2"},{"groupId":"FG004","numSubjects":"2"},{"groupId":"FG005","numSubjects":"2"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"2"},{"groupId":"FG004","numSubjects":"2"},{"groupId":"FG005","numSubjects":"1"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"0"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"1"}],"type":"Did not receive study drug"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"1"}],"type":"Extended delay in start of next cycle for reasons unrelated to treatment"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"}],"type":"Patient off-treatment for other complicating disease"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"6"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"12"},{"groupId":"FG004","numSubjects":"12"},{"groupId":"FG005","numSubjects":"7"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"10"},{"groupId":"FG001","numSubjects":"5"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"6"},{"groupId":"FG004","numSubjects":"7"},{"groupId":"FG005","numSubjects":"2"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"6"},{"groupId":"FG004","numSubjects":"5"},{"groupId":"FG005","numSubjects":"5"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Patients with recurrent/progressive diffuse intrinsic pontine glioma (DIPG) were enrolled on stratum 1, and patients with non-progressed DIPG or H3K27M+ thalamic diffuse malignant glioma (DMG) were enrolled on stratum 2.","recruitmentDetails":"Patients between 2 and 22 years of age (\\>= 2, \\< 22) at the time of enrollment were enrolled at Pediatric Brain Tumor Consortium (PBTC) member institutions. The first patient on study was enrolled on June 28, 2016, and the last patient was enrolled on November 10, 2021."}